(37) showed that MRD at day 19 of induction had a significant impact on ETV6/RUNX1-positive B-ALL and had a guiding prognostic judgment, and a subsequent research confirmed that children with MRD ≥ 0.1% were at greater risk of treatment failure or relapse. This evidence concerns the gene RUNX1 and acute lymphoblastic leukemia.